Patents by Inventor Nicholas Clayton

Nicholas Clayton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
    Patent number: 10111962
    Abstract: Provided herein are peptide-linked morpholino (PPMO) antisense oligonucleotides that target the poly CUG repeat tract in the 3? untranslated region of the gene encoding dystrophia myotonica-protein kinase (DMPK) and methods for systemic administration of the same for the treatment of mytonic dystrophy type I (DM1).
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 30, 2018
    Assignee: Genzyme Corporation
    Inventors: Andrew Leger, Bruce Wentworth, Carol A. Nelson, Timothy E. Weeden, Nicholas Clayton, Seng Cheng
  • PEPTIDE-LINKED MORPHOLINO ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF MYOTONIC DYSTROPHY
    Publication number: 20150238627
    Abstract: Provided herein are peptide-linked morpholino (PPMO) antisense oligonucleotides that target the poly CUG repeat tract in the 3? untranslated region of the gene encoding dystrophia myotonica-protein kinase (DMPK) and methods for systemic administration of the same for the treatment of mytonic dystrophy type I (DM1).
    Type: Application
    Filed: September 24, 2013
    Publication date: August 27, 2015
    Applicant: Genzyme Corporation
    Inventors: Andrew Leger, Bruce Wentworth, Carol A. Nelson, Timothy E. Weeden, Nicholas Clayton, Seng Cheng